HUADONG MEDICINE's innovative GLP-1/GIP dual-target long-acting agonist Pralmorelin injection's new veterinary drug registration application has been accepted by the Ministry of Agriculture and Rural Affairs

On December 26th, Huadong Medicine Co., Ltd.'s wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. received the "Acceptance Notice" issued by the Ministry of Agriculture and Rural Affairs of the People's Republic of China (Pralmorelin Injection Acceptance Number: 07050020250624-8, Pralmorelin Acceptance Number: 07050020250619-2). The application for the registration of the new veterinary drug Pralmorelin Injection under the HDM7006 project has been accepted, with the declared indication being: weight management for adult obese cats